Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00072124 · ClinicalTrials.gov registry record · Phase 3
Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
NCT00072124: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00072124 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00072124, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy, such as dacarbazine and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Complete metastasectomy may be an effective treatment for metastatic melanoma and may improve quality of life and help patients live longer and more comfortably. It is not yet known whether complete metastasectomy is more effective than chemotherapy in treating stage IV melanoma. PURPOSE: This randomized phase III trial is studying dacarbazine and/or cisplatin to see how well they work compared to complete metastasectomy in treating patients with stage IV melanoma.
Interventions
- DRUG cisplatin
- PROCEDURE conventional surgery
- DRUG dacarbazine
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-09 |
| Est. Completion | 2005-05 |
| Phase | Phase 3 |
What the finished NCT00072124 record still lists
NCT00072124 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00072124 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00072124 about?
NCT00072124 is a clinical study titled "Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma". RATIONALE: Drugs used in chemotherapy, such as dacarbazine and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Complete metastasectomy may be an effective treatment for metastatic melanoma and may improve quality of life and help patients live longer ...
What is the current status of trial NCT00072124?
This trial is currently completed. It is a Phase 3 study. The study started on 2003-09. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00072124?
The interventions under investigation include: cisplatin (DRUG), conventional surgery (PROCEDURE), dacarbazine (DRUG).
Who is sponsoring clinical trial NCT00072124?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia